Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2025 11:12 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (“Salarius” or the “Company”) today announced that its 2025 Annual Meeting of Stockholders (the “Annual...
December 18, 2025 07:50 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Salarius Pharmaceuticals to change the company name to Decoy Therapeutics in early January 2026
December 01, 2025 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Salarius subsidiary Decoy Therapeutics’ influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding to the viral target entry protein,...
November 19, 2025 14:42 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates...
November 13, 2025 08:45 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Salarius Pharmaceuticals and Decoy Therapeutics complete merger
October 13, 2025 08:45 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Salarius regains compliance with all Nasdaq listing requirements
September 09, 2025 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 14, 2025 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
July 14, 2025 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard

Salarius Pharmaceuticals granted additional extention to regain Nasdaq compliance
July 09, 2025 08:30 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy...